Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online

Anti-C3/C3b antibody (ab48611)

Submit a review Q&A (2)References (1)

Key features and details

  • Rabbit polyclonal to C3/C3b
  • Suitable for: ELISA, EIA, IP, ICC/IF, RIA, WB
  • Reacts with: Human
  • Isotype: IgG

Get better batch-to-batch reproducibility with a recombinant antibody

Product image
Anti-C3 / C3a antibody [EPR2987(2)(ABC)(B)] (ab171080)
  • Research with confidence – consistent and reproducible results with every batch
  • Long-term and scalable supply – powered by recombinant technology for fast production
  • Success from the first experiment – confirmed specificity through extensive validation
  • Ethical standards compliant – production is animal-free

Overview

  • Product name

    Anti-C3/C3b antibody
    See all C3/C3b primary antibodies

  • Description

    Rabbit polyclonal to C3/C3b

  • Host species

    Rabbit

  • Tested applications

    Suitable for: ELISA, EIA, IP, ICC/IF, RIA, WBmore details

  • Species reactivity

    Reacts with: Human

  • Immunogen

    C3 purified from human plasma

  • General notes

    The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.

    If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As

Properties

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab48611 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA
Use at an assay dependent concentration.
EIA
Use at an assay dependent concentration.
IP
Use at an assay dependent concentration.
ICC/IF
Use at an assay dependent concentration.
RIA
Use at an assay dependent concentration.
WB
Use at an assay dependent concentration.
Notes
ELISA
Use at an assay dependent concentration.
EIA
Use at an assay dependent concentration.
IP
Use at an assay dependent concentration.
ICC/IF
Use at an assay dependent concentration.
RIA
Use at an assay dependent concentration.
WB
Use at an assay dependent concentration.

Target

  • Function

    C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
    Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.

  • Tissue specificity

    Plasma.

  • Involvement in disease

    Defects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:120700]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
    Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
    Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.

  • Sequence similarities

    Contains 1 anaphylatoxin-like domain.
    Contains 1 NTR domain.

  • Post-translational
    modifications

    C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
    Phosphorylation sites are present in the extracelllular medium.

  • Cellular localization

    Secreted.
  • Information by UniProt

  • Database links

    • Alternative names

      • Acylation stimulating protein cleavage product antibody
      • AHUS5 antibody
      • ARMD9 antibody
      • ASP antibody
      • C3 and PZP like alpha 2 macroglobulin domain containing protein 1 antibody
      • C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 antibody
      • C3 antibody
      • c3 complement antibody
      • C3adesArg antibody
      • CO3_HUMAN antibody
      • Complement C3 alpha chain antibody
      • Complement C3 antibody
      • Complement C3b alpha' chain antibody
      • Complement C3c alpha' chain fragment 1 antibody
      • Complement C3c alpha' chain fragment 2 antibody
      • Complement C3c alpha'' chain fragment 2 antibody
      • Complement C3d fragment antibody
      • Complement C3dg fragment antibody
      • Complement C3f fragment antibody
      • Complement C3g fragment antibody
      • Complement component 3 antibody
      • Complement factor 3 antibody
      • CPAMD1 antibody
      • HEL S 62p antibody
      • omplement C3 beta chain antibody
      see all

    References (1)

    Publishing research using ab48611? Please let us know so that we can cite the reference in this datasheet.

    ab48611 has been referenced in 1 publication.

    • Wong EK  et al. Characterization of a Factor H Mutation That Perturbs the Alternative Pathway of Complement in a Family with Membranoproliferative GN. J Am Soc Nephrol N/A:N/A (2014). Human . PubMed: 24722444

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    1-2 of 2 Abreviews or Q&A

    Question

    Dear Tech support, Is there any new data regarding antibodies ab48342, ab48611? One of my customers wishes to perform "IP" of C3 in Human cells and insists on receiving experimental data, figures or specific protocol for one of these antibodies in order for him to place an order. Please advice. Regards,

    Read More
    Answer

    Thank you for your enquiry. I have been in touch with the source of these antibodies, and they have kindly provided the following IP protocol. Please note that this may require some further optimization in your own laboratory: IP protocol is as follows: 1. Have high binding protein A beads (from Peirce) in a column with 3 ml beads bed 2. Wash column with Glycine pH 3.5 (0.1 mM) with 2 column of volume 3. Wash 1x with 1 column volume of PBS 7.4 4. Add 400 ug of antibody to the beads and incubate for 2 hours at room temp with rotating 5. Wash with PBS 2 column volumes 6. Add cell lysates or tissue extract to the column and incubate for 2 hours at room temp. 7. Wash 2 x with PBS 8. Elute the protein and antibody with Glycine pH3.5 (0.1 mM) into the 50 ml conical tube with 250 ul of 1 M tris base as neutralization agent. (collect 25 ml) 9. Concentrate the elution liquid by lyophilization or concentrator. 10. Run SDS to determine the antigen. This method is for samples with low C3 protein expression. You can also try to coat the antibody to high binding plate and do the IP directly from the plate. The concept is similar but just smaller scale. I am sorry there are no further images to provide on this occasion. I hope this will be helpful to you. SHould you have any further questions, please do not hesitate to contact us.

    Read More

    Question

    ab48611 C3 antibody Will this product react with C3 breakdown products?

    Read More
    Answer

    Thank you for your patience in this matter. The originator of ab48611 (C3 antibody) has informed us that they have not tested this antibody against C3 breakdown products. As we discussed on the phone, I think that some of the product would recognize some of the breakdown products but this has not been confirmed. I'm sorry that I can not provide you with more information.

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com